NASDAQ:AVXL

SHAREHOLDER ALERT: Anavex Life Sciences Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

Retrieved on: 
Tuesday, March 26, 2024
Patient, Certification, Block & Leviton, Rett syndrome, Clinical trial, Cryptocurrency

BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Anavex Life Sciences Corp. (NASDAQ: AVXL) for securities law violations.

Key Points: 
  • BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Anavex Life Sciences Corp. (NASDAQ: AVXL) for securities law violations.
  • Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses.
  • The study failed to show statistical significance towards its primary endpoints, causing shares of Anavex Life Sciences Corp. stock to drop approximately 35%.
  • Block & Leviton is widely regarded as one of the leading securities class action firms in the country.

ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Anavex Life Sciences Corporation

Retrieved on: 
Monday, March 25, 2024
Central nervous system, District court, Patient, CNS, Research, Neurodevelopmental disorder, News, Avatar, Rett syndrome, Complaint, Action Replay, Excellence, FDA, Central nervous system disease, Court, Advertising

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Key Points: 
  • NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
    Do you, or did you, own shares of Anavex Life Sciences Corporation (NASDAQ: AVXL)?
  • If you wish to serve as lead plaintiff, you must move the Court no later than May 13, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

AVXL INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences Corporation Investors with Substantial Losses Have Opportunity to Lead Case

Retrieved on: 
Monday, March 25, 2024
Central nervous system, Patient, SAN, News, Rett, Rett syndrome, Complaint, Excellence, Tobacco

), the Anavex class action lawsuit charges Anavex as well as Anavex executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the Anavex class action lawsuit charges Anavex as well as Anavex executives with violations of the Securities Exchange Act of 1934.
  • Lead plaintiff motions for the Anavex class action lawsuit must be filed with the court no later than May 13, 2024.
  • A lead plaintiff acts on behalf of all other class members in directing the Anavex class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Anavex class action lawsuit.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Anavex Life Sciences Corp. - AVXL

Retrieved on: 
Saturday, March 23, 2024
Prior, News, Ext, LLP, Complaint, Excellence, Pomerantz, Action Replay, Court

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL).

Key Points: 
  • NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • The class action concerns whether Anavex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hut 8, Anavex, and Innoviz and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 23, 2024
Bitcoin, Research, Bankruptcy, Patient, Defendant, News, Data mining, Rett syndrome, Complaint, Hut 8, P.C, Clinical trial, MCI, Radar, Mergers and acquisitions, Cryptocurrency

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • Additional information about each case can be found at the link provided.
  • In November 2023, Hut 8 formed following the merger of Hut 8 Mining Corp. (“Legacy Hut”) and U.S. Data Mining Group, Inc. d/b/a US Bitcoin Corp. (“USBTC”) (the “Merger”).
  • For more information on the Innoviz class action go to: https://bespc.com/cases/INVZ

DEADLINE ALERT for VTYX, IRBT, and AVXL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Friday, March 22, 2024
Psoriasis, Law, Amazon, Defendant, IPO, Avatar, Suite, Complaint, Investment, Excellence, IRobot, Security (finance)

LOS ANGELES, March 22, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, March 22, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • The Law Offices of Frank R. Cruz, Los Angeles

AVXL Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Anavex Life Sciences Corporation Class Action

Retrieved on: 
Thursday, March 21, 2024
Rett, Excellence, Central nervous system, Patient, SAN, CNS, Rett syndrome, Complaint, News, LLP, Person, Pharmaceutical industry

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.

Key Points: 
  • SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.
  • What Now: You may be eligible to participate in the class action against Anavex Life Sciences Corporation.
  • Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by May 13, 2024.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Levi & Korsinsky Notifies Shareholders of Anavex Life Sciences Corporation(AVXL) of a Class Action Lawsuit and an Upcoming Deadline

Retrieved on: 
Thursday, March 21, 2024
Telephone, Patient, News, LLP, CLASS, Rett syndrome, Clinical trial, MCI, Radar, NEXT, COST, Court, Cryptocurrency

NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Anavex Life Sciences investors who were adversely affected by alleged securities fraud between February 1, 2022 and January 1, 2024.
  • Follow the link below to get more information and be contacted by a member of our team:
    AVXL investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Thursday, March 21, 2024
Central nervous system, Patient, CNS, Research, Neurodevelopmental disorder, News, Avatar, Rett syndrome, Complaint, Fraud, Excellence, FDA, Central nervous system disease, Court, Person, Pharmaceutical industry

Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.

Key Points: 
  • Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Anavex you have until May 13, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Shareholders of Anavex Life Sciences Corporation Should Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights – AVXL

Retrieved on: 
Wednesday, March 20, 2024
Patient, News, Rett syndrome, Clinical trial, MCI, Fraud, Radar, NEXT, Security (finance)

NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation.

Key Points: 
  • NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation.
  • Shareholders who purchased shares of AVXL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • ANAVEX®2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.